A Healthcare

Agilent Technologies, Inc.

$175.46+2.02%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Diagnostics & Research
Country: United States
Market cap: 49.5B USD
Enterprise value: 51.0B USD
Full-time employees: 18,200

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.21 vs a peer median of 0.63) and more debt relative to equity (0.54× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.21 vs peers 0.63) and more debt vs equity (0.54× vs peers 0.22×)
About average: growth and valuation

Ranks #552 of 1,157 healthcare companies (top 48%)

See how it ranks against its peers

Worth knowing

Wide margins. Operating margin 22% (12 months to Jul 2026) vs a peer median of 7.1%.Operating margin 22% vs peers 7.1%.
Agilent Technologies keeps 22% of revenue as operating profit, more than 84% of peers (median 7.1%).

StockQuotient Score

53/ 100

Oct 5 53 → Nov 4 53

Valuation

Is the price right?

53/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Helped by:

▲ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield2.9%

SEC filings · 12 months to Jul 2026Reported value30% base weight · Z-score 0.97Sector median: 0.0148 · MAD: 0.0148

EBITDA yield3.7%

SEC filings · 12 months to Jul 2026Reported value50% base weight · Z-score -0.08Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield2.6%

SEC filings · 12 months to Jul 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield14.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

48/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ EPS growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth18.7%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score 0.30Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth1.8%

SEC filings · 3 years to Jul 2026Reported value33% base weight · Z-score -0.48Sector median: 0.0584 · MAD: 0.0840

Revenue growth8.6%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score 0.26Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

86/100

Strong

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ ROA
▲ Operating margin
▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin22.2%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score 1.25Sector median: 0.0706 · MAD: 0.1217

Return on assets10.3%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score 1.61Sector median: 0.0166 · MAD: 0.0537

Return on invested capital13.6%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score 0.88Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin53.8%

SEC filings · 12 months to Jul 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity19.6%

SEC filings · 12 months to Jul 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.21

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.72Sector median: 0.6250 · MAD: 0.3380

Current ratio2.05×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.39Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.54×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.54Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Agilent Technologies

Is Agilent Technologies getting weaker?: Its latest SEC filing (Sep 1, 2026) showed no major changes. Its overall score is unchanged at 53/100 since Oct 28, 2026.
How is Agilent Technologies valued vs its peers?: Priced about in line with its peers. Valuation scores 53/100 against 1,393 healthcare peers. Earnings yield 2.9% vs a peer median of 1.5% (stronger than 61% of peers).Earnings yield 2.9% vs peers 1.5% (stronger than 61% of peers).
Is Agilent Technologies growing?: At about the same pace as its peers. Growth scores 48/100 against 1,393 healthcare peers. Earnings per share growth 18.7% vs a peer median of 9.8% (stronger than 68% of peers).Earnings per share growth 18.7% vs peers 9.8% (stronger than 68% of peers). 3-year revenue growth 1.8% vs a peer median of 5.8% (weaker than 65% of peers).3-year revenue growth 1.8% vs peers 5.8% (weaker than 65% of peers).
How profitable is Agilent Technologies?: More profitable than most of its peers. Profitability scores 86/100 against 1,393 healthcare peers. Return on assets 10.3% vs a peer median of 1.7% (stronger than 90% of peers).Return on assets 10.3% vs peers 1.7% (stronger than 90% of peers).
How risky is Agilent Technologies?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.21 vs a peer median of 0.63 (weaker than 80% of peers).Beta 1.21 vs peers 0.63 (weaker than 80% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jul 31, 2026 · filed Sep 1, 2026 · compared with the quarter ended Apr 30, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	7.2B USD	7.4B USD	+1.9%
Net income (12 months)	1.4B USD	1.4B USD	+1.8%
Operating margin	21.5%	22.2%	+0.7 pts
Free cash flow (12 months)	1.1B USD	1.3B USD	+16.6%
Debt	3.4B USD	3.9B USD	+17.7%
Cash	1.8B USD	1.8B USD	−2.7%
Shares outstanding	282.4M	281.9M	−0.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Diagnostics & Research · 26 companies

Valuations in Diagnostics & Research are within their usual range since Nov 2018.

53% of months since Nov 2018 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +109% vs the whole market, against a usual +111%.

Nov 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Oct 2021	FY Oct 2022	FY Oct 2023	FY Oct 2024	FY Oct 2025	Change
Gross margin	53.9%	54.4%	50.7%	54.3%	52.4%	▼ 1.9 pts
Operating margin	21.3%	23.6%	19.8%	22.9%	21.3%	▼ 1.6 pts
Net margin	19.1%	18.3%	18.1%	19.8%	18.8%	▼ 1.0 pts
Return on assets (ROA)	11.3%	11.9%	11.5%	10.9%	10.2%	▼ 0.6 pts
Return on equity (ROE)	22.5%	23.6%	21.2%	21.9%	19.3%	▼ 2.5 pts
Free cash flow margin	20.5%	14.9%	21.6%	21.1%	16.6%	▼ 4.5 pts
Current ratio	2.22×	2.03×	2.61×	2.09×	1.96×	▼ 6.3%
Quick ratio	1.74×	1.47×	1.97×	1.58×	1.52×	▼ 3.5%
Debt to equity	0.51×	0.52×	0.47×	0.57×	0.50×	▼ 13%
Interest coverage	16.63×	19.26×	14.21×	15.50×	13.21×	▼ 15%

A price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.21 vs a peer median of 0.63) and more debt relative to equity (0.54× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.21 vs peers 0.63) and more debt vs equity (0.54× vs peers 0.22×)

About average: growth and valuation

Ranks #552 of 1,157 healthcare companies (top 48%)

See how it ranks against its peers

Questions investors ask about Agilent Technologies

Is Agilent Technologies getting weaker?

Its latest SEC filing (Sep 1, 2026) showed no major changes. Its overall score is unchanged at 53/100 since Oct 28, 2026.

How is Agilent Technologies valued vs its peers?

Priced about in line with its peers. Valuation scores 53/100 against 1,393 healthcare peers. Earnings yield 2.9% vs a peer median of 1.5% (stronger than 61% of peers).Earnings yield 2.9% vs peers 1.5% (stronger than 61% of peers).

Is Agilent Technologies growing?

At about the same pace as its peers. Growth scores 48/100 against 1,393 healthcare peers. Earnings per share growth 18.7% vs a peer median of 9.8% (stronger than 68% of peers).Earnings per share growth 18.7% vs peers 9.8% (stronger than 68% of peers). 3-year revenue growth 1.8% vs a peer median of 5.8% (weaker than 65% of peers).3-year revenue growth 1.8% vs peers 5.8% (weaker than 65% of peers).

How profitable is Agilent Technologies?

More profitable than most of its peers. Profitability scores 86/100 against 1,393 healthcare peers. Return on assets 10.3% vs a peer median of 1.7% (stronger than 90% of peers).Return on assets 10.3% vs peers 1.7% (stronger than 90% of peers).

How risky is Agilent Technologies?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.21 vs a peer median of 0.63 (weaker than 80% of peers).Beta 1.21 vs peers 0.63 (weaker than 80% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

7.2B USD

7.4B USD

+1.9%

Net income (12 months)

1.4B USD

1.4B USD

+1.8%

Operating margin

21.5%

22.2%

+0.7 pts

Free cash flow (12 months)

1.1B USD

1.3B USD

+16.6%

Debt

3.4B USD

3.9B USD

+17.7%

Cash

1.8B USD

1.8B USD

−2.7%

Shares outstanding

282.4M

281.9M

−0.2%

Key ratios

FY Oct 2021

FY Oct 2022

FY Oct 2023

FY Oct 2024

FY Oct 2025

Change

Gross margin

53.9%

54.4%

50.7%

54.3%

52.4%

▼ 1.9 pts

Operating margin

21.3%

23.6%

19.8%

22.9%

21.3%

▼ 1.6 pts

Net margin

19.1%

18.3%

18.1%

19.8%

18.8%

▼ 1.0 pts

Return on assets (ROA)

11.3%

11.9%

11.5%

10.9%

10.2%

▼ 0.6 pts

Return on equity (ROE)

22.5%

23.6%

21.2%

21.9%

19.3%

▼ 2.5 pts

Free cash flow margin

20.5%

14.9%

21.6%

21.1%

16.6%

▼ 4.5 pts

Current ratio

2.22×

2.03×

2.61×

2.09×

1.96×

▼ 6.3%

Quick ratio

1.74×

1.47×

1.97×

1.58×

1.52×

▼ 3.5%

Debt to equity

0.51×

0.52×

0.47×

0.57×

0.50×

▼ 13%

Interest coverage

16.63×

19.26×

14.21×

15.50×

13.21×

▼ 15%